Titre : Fièvre jaune

Fièvre jaune : Questions médicales fréquentes

Termes MeSH sélectionnés :

Immunization Programs
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Fièvre jaune : Questions médicales les plus fréquentes", "headline": "Fièvre jaune : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Fièvre jaune : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-06", "dateModified": "2025-03-31", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Fièvre jaune" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Fièvres hémorragiques virales", "url": "https://questionsmedicales.fr/mesh/D006482", "about": { "@type": "MedicalCondition", "name": "Fièvres hémorragiques virales", "code": { "@type": "MedicalCode", "code": "D006482", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.925.782.417" } } }, "about": { "@type": "MedicalCondition", "name": "Fièvre jaune", "alternateName": "Yellow Fever", "code": { "@type": "MedicalCode", "code": "D015004", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Pedro Augusto Alves", "url": "https://questionsmedicales.fr/author/Pedro%20Augusto%20Alves", "affiliation": { "@type": "Organization", "name": "Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil." } }, { "@type": "Person", "name": "Erna Geessien Kroon", "url": "https://questionsmedicales.fr/author/Erna%20Geessien%20Kroon", "affiliation": { "@type": "Organization", "name": "Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil." } }, { "@type": "Person", "name": "Betânia Paiva Drumond", "url": "https://questionsmedicales.fr/author/Bet%C3%A2nia%20Paiva%20Drumond", "affiliation": { "@type": "Organization", "name": "Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil." } }, { "@type": "Person", "name": "Anna-Bella Failloux", "url": "https://questionsmedicales.fr/author/Anna-Bella%20Failloux", "affiliation": { "@type": "Organization", "name": "Institut Pasteur, Université Paris Cité, Arboviruses and Insect Vectors, Paris, France. anna-bella.failloux@pasteur.fr." } }, { "@type": "Person", "name": "Laurence Cibrelus", "url": "https://questionsmedicales.fr/author/Laurence%20Cibrelus", "affiliation": { "@type": "Organization", "name": "World Health Organisation, Geneva, Switzerland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Driving more WHO-recommended vaccines in the National Immunization Program: Issues and challenges in China.", "datePublished": "2023-04-26", "url": "https://questionsmedicales.fr/article/37099400", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/21645515.2023.2194190" } }, { "@type": "ScholarlyArticle", "name": "Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36933984", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.vaccine.2023.03.007" } }, { "@type": "ScholarlyArticle", "name": "A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.", "datePublished": "2022-06-15", "url": "https://questionsmedicales.fr/article/35703731", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/21645515.2022.2079305" } }, { "@type": "ScholarlyArticle", "name": "The faces behind vaccination: unpacking the attitudes, knowledge, and practices of staff of Cameroon's Expanded program on Immunization.", "datePublished": "2023-11-13", "url": "https://questionsmedicales.fr/article/37957695", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12960-023-00869-7" } }, { "@type": "ScholarlyArticle", "name": "Analyzing the usage of theories of change for routine immunization programs -- a review of impact evaluations from LMICs.", "datePublished": "2024-09-09", "url": "https://questionsmedicales.fr/article/39252041", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41043-024-00615-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Infection", "item": "https://questionsmedicales.fr/mesh/D007239" }, { "@type": "ListItem", "position": 3, "name": "Maladies virales", "item": "https://questionsmedicales.fr/mesh/D014777" }, { "@type": "ListItem", "position": 4, "name": "Infections à virus à ARN", "item": "https://questionsmedicales.fr/mesh/D012327" }, { "@type": "ListItem", "position": 5, "name": "Fièvres hémorragiques virales", "item": "https://questionsmedicales.fr/mesh/D006482" }, { "@type": "ListItem", "position": 6, "name": "Fièvre jaune", "item": "https://questionsmedicales.fr/mesh/D015004" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Fièvre jaune - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Fièvre jaune", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Fièvre jaune", "description": "Comment diagnostique-t-on la fièvre jaune ?\nQuels tests sont utilisés pour confirmer la fièvre jaune ?\nQuels symptômes indiquent une fièvre jaune ?\nLa fièvre jaune peut-elle être confondue avec d'autres maladies ?\nQuel rôle joue l'historique de voyage dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D015004?mesh_terms=Immunization+Programs&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Fièvre jaune", "description": "Quels sont les premiers symptômes de la fièvre jaune ?\nLa jaunisse est-elle un symptôme de la fièvre jaune ?\nQuels symptômes indiquent une forme sévère de la maladie ?\nLes symptômes de la fièvre jaune évoluent-ils rapidement ?\nPeut-on avoir des symptômes sans être infecté ?", "url": "https://questionsmedicales.fr/mesh/D015004?mesh_terms=Immunization+Programs&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Fièvre jaune", "description": "Comment se protéger contre la fièvre jaune ?\nLa vaccination est-elle efficace contre la fièvre jaune ?\nÀ quel âge peut-on se faire vacciner contre la fièvre jaune ?\nFaut-il un certificat de vaccination pour voyager ?\nLes moustiquaires sont-elles utiles pour la prévention ?", "url": "https://questionsmedicales.fr/mesh/D015004?mesh_terms=Immunization+Programs&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Fièvre jaune", "description": "Quel est le traitement principal pour la fièvre jaune ?\nLes antibiotiques sont-ils efficaces contre la fièvre jaune ?\nComment gérer la déshydratation due à la fièvre jaune ?\nDes soins intensifs sont-ils nécessaires pour les cas graves ?\nPeut-on prévenir la fièvre jaune par des traitements ?", "url": "https://questionsmedicales.fr/mesh/D015004?mesh_terms=Immunization+Programs&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Fièvre jaune", "description": "Quelles sont les complications possibles de la fièvre jaune ?\nLa fièvre jaune peut-elle entraîner la mort ?\nQuels organes peuvent être affectés par la fièvre jaune ?\nLes complications surviennent-elles rapidement ?\nPeut-on récupérer complètement après des complications ?", "url": "https://questionsmedicales.fr/mesh/D015004?mesh_terms=Immunization+Programs&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Fièvre jaune", "description": "Qui est le plus à risque de contracter la fièvre jaune ?\nLes voyageurs doivent-ils se faire vacciner avant de partir ?\nLes personnes âgées sont-elles plus vulnérables ?\nLes personnes immunodéprimées sont-elles à risque ?\nLes conditions de vie influencent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D015004?mesh_terms=Immunization+Programs&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la fièvre jaune ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur les symptômes cliniques et des tests sanguins pour détecter le virus." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer la fièvre jaune ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques et la PCR sont utilisés pour confirmer la présence du virus." } }, { "@type": "Question", "name": "Quels symptômes indiquent une fièvre jaune ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, douleurs musculaires, et jaunisse sont des symptômes clés." } }, { "@type": "Question", "name": "La fièvre jaune peut-elle être confondue avec d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec la dengue ou l'hépatite virale." } }, { "@type": "Question", "name": "Quel rôle joue l'historique de voyage dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un historique de voyage dans des zones endémiques est crucial pour le diagnostic." } }, { "@type": "Question", "name": "Quels sont les premiers symptômes de la fièvre jaune ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les premiers symptômes incluent fièvre, frissons, et douleurs musculaires." } }, { "@type": "Question", "name": "La jaunisse est-elle un symptôme de la fièvre jaune ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la jaunisse apparaît souvent dans les cas avancés de fièvre jaune." } }, { "@type": "Question", "name": "Quels symptômes indiquent une forme sévère de la maladie ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements, des douleurs abdominales et une défaillance organique signalent une forme sévère." } }, { "@type": "Question", "name": "Les symptômes de la fièvre jaune évoluent-ils rapidement ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent évoluer rapidement, nécessitant une attention médicale urgente." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans être infecté ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes similaires peuvent apparaître sans infection, nécessitant un diagnostic précis." } }, { "@type": "Question", "name": "Comment se protéger contre la fièvre jaune ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utilisez des répulsifs, portez des vêtements longs et évitez les zones à moustiques." } }, { "@type": "Question", "name": "La vaccination est-elle efficace contre la fièvre jaune ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vaccination est très efficace et recommandée pour les voyageurs dans les zones à risque." } }, { "@type": "Question", "name": "À quel âge peut-on se faire vacciner contre la fièvre jaune ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination est recommandée à partir de 9 mois." } }, { "@type": "Question", "name": "Faut-il un certificat de vaccination pour voyager ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un certificat de vaccination peut être exigé pour entrer dans certains pays." } }, { "@type": "Question", "name": "Les moustiquaires sont-elles utiles pour la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les moustiquaires traitées sont efficaces pour réduire les piqûres de moustiques." } }, { "@type": "Question", "name": "Quel est le traitement principal pour la fièvre jaune ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement antiviral spécifique; le traitement est symptomatique." } }, { "@type": "Question", "name": "Les antibiotiques sont-ils efficaces contre la fièvre jaune ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, les antibiotiques ne sont pas efficaces car la fièvre jaune est causée par un virus." } }, { "@type": "Question", "name": "Comment gérer la déshydratation due à la fièvre jaune ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'hydratation par voie intraveineuse est essentielle pour gérer la déshydratation." } }, { "@type": "Question", "name": "Des soins intensifs sont-ils nécessaires pour les cas graves ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cas graves peuvent nécessiter des soins intensifs pour surveiller les organes." } }, { "@type": "Question", "name": "Peut-on prévenir la fièvre jaune par des traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La prévention repose principalement sur la vaccination, pas sur des traitements." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de la fièvre jaune ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance hépatique, les saignements et le choc." } }, { "@type": "Question", "name": "La fièvre jaune peut-elle entraîner la mort ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fièvre jaune peut être mortelle, surtout sans traitement approprié." } }, { "@type": "Question", "name": "Quels organes peuvent être affectés par la fièvre jaune ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Le foie, les reins et le cœur peuvent être gravement affectés par la maladie." } }, { "@type": "Question", "name": "Les complications surviennent-elles rapidement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent survenir dans les 7 à 10 jours suivant l'infection." } }, { "@type": "Question", "name": "Peut-on récupérer complètement après des complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines personnes peuvent récupérer complètement, mais d'autres peuvent avoir des séquelles." } }, { "@type": "Question", "name": "Qui est le plus à risque de contracter la fièvre jaune ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes vivant ou voyageant dans des zones endémiques sont les plus à risque." } }, { "@type": "Question", "name": "Les voyageurs doivent-ils se faire vacciner avant de partir ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vaccination est fortement recommandée pour les voyageurs vers des zones à risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus vulnérables ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir un risque accru de complications graves." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées courent un risque plus élevé de maladie sévère." } }, { "@type": "Question", "name": "Les conditions de vie influencent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, vivre dans des zones avec des moustiques augmente le risque de transmission." } } ] } ] }

Sources (10000 au total)

Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.

Pakistan has a well-established Expanded Program on Immunization (EPI) however vaccine-preventable diseases still account for high infant and child mortality rates. This study describes the differenti... From October 2014 to September 2018, we enrolled children younger than 2 years of age from the Matiari Demographic Surveillance System in Sindh, Pakistan. Socio-demographic and vaccination history wer... Of the 3140 enrolled children, 48.4 % received all EPI recommended vaccines. Only 21.2 % of these were age appropriate. Around 45.4 % of the children were partially vaccinated, and 6.2 % were unvaccin... Vaccine coverage was low among children in Matiari, Pakistan, and majority received delayed doses. Parents' education status and year of study enrollment was protective against vaccine dropout and del...

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.

In response to the substantial clinical and economic burden of diseases caused by... A Markov model that simulated the disease processes of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) over a newborn cohort lifetime was used to evaluate the cost-effecti... Vaccination with PHiD-CV or PCV13 was estimated to avert approximately 700 cases of IPD (200 meningitis, 500 bacteremia), and around 5,000 cases of all-cause pneumonia. However, PHiD-CV vaccination wa... PCVs are a cost-effective strategy to relieve the burden associated with diseases caused by...

The faces behind vaccination: unpacking the attitudes, knowledge, and practices of staff of Cameroon's Expanded program on Immunization.

Immunization is regarded as one of the most cost-effective public health interventions in global health. However, its cost-effectiveness depends greatly on the knowledge and skills of vaccinators. Wit... Through a descriptive cross-sectional design, we used structured questionnaires and observation guides to collect data from vaccination staff in health facilities that were selected by a multistage sa... Overall, we collected data from Expanded Program on Immunization focal staff in 265 health facilities across 68 health districts. Over half (53%) of the surveyed facilities were found in rural areas. ... This study suggests marked deficits in immunization knowledge among vaccination staff and exposes common attitudes and practices that could contribute to missed opportunities for vaccination and hinde...

Analyzing the usage of theories of change for routine immunization programs -- a review of impact evaluations from LMICs.

In this article we analyzed the extent of the usage of Theories of Change (TOCs) and causal pathways in the evaluation of immunization programs to identify the challenges to generating evidence on how... We analyzed the use of the TOC in impact evaluations (IEs) of immunization interventions published after 2010, and its associated articles. The review includes studies from Evidence Gap Map and Yale r... Our review included 47 large-scale and 45 small-to medium-scale interventions. Of the included studies, 19% used a TOC, 56% described a causal pathway or used a conceptual diagram with varying degrees... Future implementers and evaluators need to develop clear TOCs that are based on established theory and have clearly articulated the underlying assumptions. Large-scale health system strengthening init...

Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018).

Rotavirus (RV) vaccination was included in the Finnish National immunization Program (NIP) in 2009. RotaTeq (RV5) has been used exclusively with a national average vaccination coverage rate (VCR) of >... We first describe the incidence of RVGE, viral gastroenteritis (VGE), and acute gastroenteritis (AGE) for all Finnish children born during 2008-2011. Children were stratified by the year of birth into... RVGE incidence decreased significantly soon after implementation of RV vaccination in the NIP. In vaccine-eligible cohorts, no clear peak incidence in the youngest age groups could be observed, and no... Incidence of RVGE has remained low in all age groups during the 10 years following introduction of RV vaccine in the Finnish NIP. Differences in RVGE incidence were observed in regions with high as co...

Comprehensive assessment of the implementation of maternal immunization programs in Italy: A national survey across maternity care units.

The authors aimed to assess the characteristics and integration of immunization services into the prenatal care provided by maternity care units (MCUs) in Italy.... A cross-sectional nationwide study using a web-based survey was conducted from June to August 2021. The study population consisted of 342 obstetricians/gynecologists (OB/GYNs), members of the Italian ... Overall, 112 of 342 MCUs completed the survey, for an overall response rate of 32.7%. Almost all MCUs (96.4%) provided vaccine information, but only 22% had an onsite vaccination clinic. Less than hal... Institutional barriers and lack of certain vaccine-related services offered during prenatal care in Italian MCUs might be responsible for many missed vaccination opportunities. Embedding maternal immu...

Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe.

Delaying of policies for immunization of aging adults, low vaccine uptake, and the lack of supportive evidence at the national level could diminish the value in health and economics of such programs. ... The tool was developed in two phases. First, a modified Delphi process was used to construct the tool. The process included a literature review, stakeholder consultations, and a three-round Delphi stu... The review identified 16 tools and frameworks that formed the first version of our tool with 14 items. Eight experts were involved in the Delphi panel. Through three Delphi rounds, four items were add... Through a thorough and transparent process, a country score tool was developed helping to identify strengths, weaknesses, and evidential requirements for decision-making and implementation of immuniza...